» Articles » PMID: 18339857

The Smo/Smo Model: Hedgehog-induced Medulloblastoma with 90% Incidence and Leptomeningeal Spread

Overview
Journal Cancer Res
Specialty Oncology
Date 2008 Mar 15
PMID 18339857
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Toward the goal of generating a mouse medulloblastoma model with increased tumor incidence, we developed a homozygous version of our ND2:SmoA1 model. Medulloblastomas form in 94% of homozygous Smo/Smo mice by 2 months of age. Tumor formation is, thus, predictable by age, before the symptomatic appearance of larger lesions. This high incidence and early onset of tumors is ideal for preclinical studies because mice can be enrolled before symptom onset and with a greater latency period before late-stage disease. Smo/Smo tumors also display leptomeningeal dissemination of neoplastic cells to the brain and spine, which occurs in many human cases. Despite an extended proliferation of granule neuron precursors (GNP) in the postnatal external granular layer (EGL), the internal granular layer formed normally in Smo/Smo mice and tumor formation occurred only in localized foci on the superficial surface of the molecular layer. Thus, tumor formation is not simply the result of over proliferation of GNPs within the EGL. Moreover, Smo/Smo medulloblastomas were transplantable and serially passaged in vivo, demonstrating the aggressiveness of tumor cells and their transformation beyond a hyperplastic state. The Smo/Smo model is the first mouse medulloblastoma model to show leptomeningeal spread. The adherence to human pathology, high incidence, and early onset of tumors thus make Smo/Smo mice an efficient model for preclinical studies.

Citing Articles

Sonic hedgehog signalling pathway in CNS tumours: its role and therapeutic implications.

Wireko A, Ben-Jaafar A, Kong J, Mannan K, Sanker V, Rosenke S Mol Brain. 2024; 17(1):83.

PMID: 39568072 PMC: 11580395. DOI: 10.1186/s13041-024-01155-w.


Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies.

Holmberg K, Borgenvik A, Zhao M, Giraud G, Swartling F Cancers (Basel). 2024; 16(9).

PMID: 38730706 PMC: 11083189. DOI: 10.3390/cancers16091752.


Single-fraction Radiation Treatment Dose Response in a Genetically Engineered Mouse Model of Medulloblastoma.

Tu K, Stewart C, Williams N, Ma Y, Luo L, Ghosh D Radiat Res. 2023; 200(6):587-592.

PMID: 37990957 PMC: 11037923. DOI: 10.1667/RADE-23-00126.1.


Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward.

Mishra D, Popovski D, Morris S, Bondoc A, Kumar S, Girard E Neuro Oncol. 2023; 26(2):226-235.

PMID: 37713135 PMC: 10836771. DOI: 10.1093/neuonc/noad170.


The Multiple Faces of the MRN Complex: Roles in Medulloblastoma and Beyond.

Petroni M, La Monica V, Fabretti F, Augusto M, Battaglini D, Polonara F Cancers (Basel). 2023; 15(14).

PMID: 37509263 PMC: 10377613. DOI: 10.3390/cancers15143599.